IMP: BOD resolution dated February 09, 2023

The Board resolution dated February 09, 2023, the BOD of Imexpharm Corporation announced the following issues:

1. Approved the business result in 2022:

2. Approved the business plan in 2023:

3. Approved the use of development investment fund for offsetting operating expenses in 2022 and 2023 with the total amount 17,266,310,029 dongs.
4. Approved to authorize representatives for Imexpharm’s capital in Agimexpharm Pharmaceutical Joint-Stock Company:

- Ms. Tran Thi Dao – Deputy Chairman of the BOD, General Director

- Mr. Nguyen Quoc Dinh – Chairman of the BOD, Deputy General Director.

HOSE

>   HT1: Agreement with VICEM E&E., JSC (10/02/2023)

>   SVC: Reminder of information disclosure (10/02/2023)

>   VNE: Reminder of information disclosure (10/02/2023)

>   EIB: Closing the ownership ratio limit (10/02/2023)

>   HBC: Reminder of information disclosure (10/02/2023)

>   BCG: Approving the transaction with related parties in Quarter 1.2023 (10/02/2023)

>   NHH: Approving the transaction with related parties in 2023 (10/02/2023)

>   CMV: BOD resolution dated Feb 08, 2023 (10/02/2023)

>   STB.ACBS.Call.EU.Cash.9M.31: SSC grants a covered warrant license (10/02/2023)

>   HPG.ACBS.Call.EU.Cash.9M.29: Report on distribution result of covered warrant (10/02/2023)